

NOVARTIS NEN

NOVARTIS **NEN**

Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan:

a nationwide survey analysis

Ito T, et al. J Gastroenterol. 2015; 50: 58-64

NOVARTIS NEN

NEN ¹ SEER (Surveillance, Epidemiology, and End Results) study 1973-2012 6.4/10 1.09 6.98 ² 2005 NEN 3 ³ 1 MEN1 NEN ⁴ 2010 2 ⁵ 2005 2016

NOVARTIS

1 ³

2005 1 12 31 5,773 1 2 1 621 951 NEN 368 NEN 583 2 951 344 36.2

2 ⁴

2010 1 12 31 1 NEN 6,339 3,366 NEN 1,273 NEN 2,093 20.2

NOVARTIS NEN

2010 NEN 3,379 2005 1.2 1 10 2.69 1 10 1.27 2005 0.50 2010 0.41 2005 0.51 2010 0.87 1.7 NEN 65.5 34.5 2005 42.8 5 20.9 8.2 3.2 VIP 0.6 0.3

2010 WHO NET G1/G2 NEC NEN 7.5 3.2 9.7
 NEN 19.9 16.9 21.3 2 30.2 9.3 WHO G1/G2 12.9 NEC 46.3 NEC 51.9 MEN1 NEN 4.3 4.9 4.0 2 MEN1 16.3 0.8

1 NEN 2005 2010

	2005 ³	2010 ⁴
NEN 1	2,845 95% CI:2,455~3,507	3,379 95% CI:3,173~3,580
	1,627 95% CI:1,404~2,005	1,105 95% CI:868~1,342
	1,218 95% CI:1,053~1,453	2,274 95% CI:1,759~2,789
10	2.23 95% CI:1.93~2.76	2.69 95% CI:2.29~3.08
	1.27 95% CI:1.10~1.57	0.88 95% CI:0.65~1.05
	0.95 95% CI:0.82~1.17	1.81 95% CI:1.51~2.11
1 10	1.01 95% CI:0.88~1.25	1.27 95% CI:1.08~1.46
	0.50 95% CI:0.44~0.62	0.41 95% CI:0.32~0.48
	0.51 95% CI:0.88~1.25	0.87 95% CI:0.72~1.01

95% CI:95%

2 NEN MEN1

	%			MEN1 %
	Total	NET G1/G2	NEC	
NEN	19.9	12.9	46.3	4.3
NEN	16.9	17.2	14.3	4.9
	9.3	9.7	0	0.8
	30.2	32.4	10.7	16.3
	8.3	9.1	0	8.3
VIP	80.0	80.0	0	0
	100	100	0	0
	25.0	0	50.0	0
NEN	21.3	12.9	51.9	4.0

NEN

2010 NEN 8,088 2005 1.8 3 10 6.42
 1 10 3.51 26.1 3.6 70.3 2005
 2005

WHO NEC NEN 6.2 12.6 9.1 2.3

6.0 8.6 9.8 3.5 WHO G1/G2 2.7
 NEC 32.3 40.9

MEN1 0.42 0.72 0 0.16
 3.2 17.1 4.2 1.1

3 NEN 2005 2010

	2005 ³	2010 ⁴
NEN 1	4,406 95% CI: 3,321~5,420	8,088 95% CI: 5,669~10,507
	1,338 95% CI: 1,009~1,640	2,107 95% CI: 1,189~3,028
	423 95% CI: 319~520	290 95% CI: 271~349
	2,645 95% CI: 1,994~3,254	5,690 95% CI: 3,583~7,797
10	3.45 95% CI: 1.93~4.24	6.42 95% CI: 4.50~8.34
	1.05 95% CI: 0.59~1.28	1.67 95% CI: 0.94~2.40
	0.33 95% CI: 0.18~0.41	0.23 95% CI: 0.18~0.28
	2.07 95% CI: 1.56~2.55	4.52 95% CI: 3.17~5.87
1 10	2.10 95% CI: 1.56~2.54	3.51 95% CI: 2.50~4.53
	0.64 95% CI: 0.48~0.77	1.20 95% CI: 0.48~1.91
	0.20 95% CI: 0.15~0.24	0.15 95% CI: 0.12~0.18
	1.26 95% CI: 0.94~1.52	2.12 95% CI: 1.56~2.67

2005 2010 NEN 42.8 65.5^{2 6 7}
 NEN EUS-FNA^{8 9} NEN
 2005 30 60^{2 10 11}
^{12~15} NEN NEN
 MEN1 NEC NEC
 NEN 7.5 46.3 51.9 NEC NEN 6.2
 32.3 NEN

2016⁵

2016 NEN 6,735 NEN

000000**NEN**000


0000000000100000000000**NEN**1,336000000**NEN**5,399000000
 1000000000001000000000**NEN**0.70000000**NEN**2.840000000400
 00000000053%0000000000020%0013%000005%0003%0003%0002%000/001%000000010000
 00000000200500000³000**NEN**57.6000000**NEN**59.80000000020160000000**NEN**6500000000
 00
 000000000000000000000000051.8%000000000**NEN**0000000000000000000000000000000000000
 0**NEN**00

04 00000000000**NEN**0000/000000**2016**00000000000⁵⁰

0000	00000000			00000000/10000000		
	00	00	00	00	00	00
00	707	629	1336	0.362	0.335	0.697
00	200	62	262	0.074	0.025	0.098
0	775	267	1042	0.309	0.120	0.482
0000	264	178	442	0.112	0.083	0.195
00/00	65	32	97	0.031	0.016	0.046
00	55	50	105	0.039	0.035	0.074
00	157	121	278	0.069	0.050	0.118
00	1911	1262	3173	1.099	0.723	1.822
000NEN	3427	1972	5399	1.733	1.051	2.835
00	4134	2601	6735	2.094	1.385	3.532

01 00000**NEN**00000000000**2016**00000000000⁵⁰

Image



Masui T, Ito T, et al. BMC Cancer. 2020; 20: 1104.

□□□

1. Metz DC, et al. Gastroenterology. 2008; 135: 1469-1492
2. Dasari A, et al. JAMA Oncol. 2017; 3: 1335-1342
3. Ito T, et al. J Gastroenterol. 2010; 45: 234-243
4. Ito T, et al. J Gastroenterol. 2015; 50: 58-64
5. Masui T, Ito T, et al. BMC Cancer. 2020; 20: 1104
6. Yao JC, et al. J Clin Oncol. 2008; 26: 3063-3072
7. Pape UF, et al. Ann N Y Acad Sci. 2004; 1014: 222-233
8. Falconi M, et al. Neuroendocrinology. 2012; 95: 120-134
9. Haba S, et al. J Gastroenterol. 2013; 48: 973-981
10. Hosoda W, et al. Pathol Int. 2010; 60: 358-364

11. Pavel M, et al. Neuroendocrinology. 2012; 95: 157-176
12. Oberg K, Expert Rev Anticancer Ther. 2003; 3: 863-877
13. Tsai HJ, et al. PLoS One. 2013; 22: e62487
14. Wang YH, et al. BMC Endocr Disord. 2012; 29: 30
15. Cho MY, et al. Cancer Res Treat. 2012; 44: 157-165
16. Lim T, et al. Asia Pac J Clin Oncol. 2011; 7: 293-299

□□□□□□□□□□□□□□□□

□□□□□□

Source URL: <https://www.pro.novartis.com/jp-ja/products/lutathera/disease/02>